5:14 PM
Oct 10, 2017
 |  BC Extra  |  Company News

Ultragenyx's burosumab gets Priority Review for XLH

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said FDA accepted and granted Priority Review to a BLA for burosumab (KRN23, UX023) to treat X-linked hypophosphatemia (XLH) in adult and...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >